Objectives. To evaluate the clinical efficacy and tolerability of etoricoxib in the treatment of osteoarthritis (OA) of the knee and define the clinically active dose range for further clinical trials.
Agents that selectively inhibit the enzyme cyclooxygenase (COX) 2 isoform (COX-2), including rofecoxib and celecoxib, were developed to provide clinical efficacy comparable to non-selective NSAIDs with a reduced risk of gastrointestinal (GI) toxicity. Previous studies have shown that these agents inhibit COX-2 to a greater degree than COX-1, with varying degrees of selectivity, and that they impart important therapeutic benefits w1-8x. Large-scale clinical GI outcome trials of celecoxib and rofecoxib have shown a significant risk reduction in the development of gastromucosal injuries compared with non-selective NSAIDs w5, 8x. Etoricoxib w5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl) pyridinex (Merck; also known as MK-0663) is a novel dipyridinyl agent that selectively inhibits COX-2. Etoricoxib is more than 100-fold selective for COX-2 vs COX-1 in whole-blood assays w9x, and has similar efficacy to traditional NSAIDs in various rodent models of inflammation, pain and fever, and also in a primate model of pyresis w9x. Furthermore, etoricoxib selectively inhibits COX-2 in humans and is more selective in vitro than any COX-2-selective NSAID currently available w9, 10x. Etoricoxib has a half-life of approximately 25 h w11x, which supports once-daily dosing. This study was undertaken to evaluate the efficacy and safety of etoricoxib in patients with osteoarthritis (OA) of the knee and to refine the dose selection for further clinical investigation.
Methods
This study was conducted in accordance with guidelines for the ethical treatment of study patients, as outlined in the Declaration of Helsinki. All subjects gave written informed consent before any study procedures were performed. The study protocol and procedures were approved by the appropriate institutional review board (IRB) for each investigative site. IRBs that approved the study include the Western IRB, Saint Luke's Medical Center, Providence IRB, Preventive and Nutrition Medicine Clinic Human Investigation Committee, University of Utah Health Sciences Center IRB, Hospital for Special Surgery Review Board, and the Northwestern University Office for the Protection of Research Subjects.
Study design
This was a two-part dose-finding study conducted over 14 weeks (Fig. 1) . The study objectives were to demonstrate the clinical efficacy of etoricoxib in the treatment of OA of the knee, to define the clinically active dose range of etoricoxib in the treatment of OA in order to permit dose selection for further clinical trials, and to evaluate the overall safety and tolerability of etoricoxib with once-daily administration.
Part 1 was a 6-week, placebo-controlled period. At the beginning of Part 1, eligible patients were randomized according to a computer-generated allocation schedule (1:2:2:2:2:2) to placebo, etoricoxib 5, 10, 30, 60 or 90 mg once daily. The allocation schedule was generated by a project statistician. Patients were given blister packs of medication by study site personnel; each blister pack was labelled with an allocation number and assigned in the order in which patients were enrolled. Investigators and patients remained blinded to individual patient allocation throughout the study.
Part 2 was an 8-week active comparator-controlled period. Treatments in Part 2 were etoricoxib 30, 60 and 90 mg once daily and diclofenac 50 mg three times daily, and were preassigned by the same allocation schedule as that used in Part 1. Patients receiving etoricoxib 5 or 10 mg or placebo in Part 1 received etoricoxib 30 mg or diclofenac in Part 2. Half of those patients receiving etoricoxib 30 or 60 mg in Part 1 received etoricoxib 60 or 90 mg respectively in Part 2, and the remaining patients received the same study medication during Part 1 and Part 2.
Study blinding was maintained by using a matching placebo for each study medication; all treatments were double-dummy. In Part 1, patients took two tablets each morning. In Part 2, patients took three tablets each morning (etoricoxib 30 mg or placebo, etoricoxib 60 mg or placebo, and diclofenac or placebo), one tablet (diclofenac or placebo) at midday and one (diclofenac or placebo) in the evening. After completing 2 weeks of treatment, patients were provided open-label acetaminophen, maximum daily dose of 2.6 g, that could be taken for osteoarthritic pain that was not adequately controlled by the study medication. Patients returned to the study centre following 1, 2, 4, 6, 8 and 14 weeks of therapy for efficacy and safety assessments. Patients who did not enter a voluntary extension at the end of Part 2 returned 7-10 days after their last dose of study medication for post-therapy safety assessments.
Entry criteria
Patients were a minimum of 40 yr old and had both clinical and radiographic evidence of OA. Patients with OA of the knee (tibiofemoral joint only) were eligible. Radiographic criteria were joint-space narrowing with the presence of osteophytes. The study joint had to be the primary source of pain or disability. Patients were in American Rheumatism Association (ARA) functional class I, II or III. All patients required NSAIDs for their OA pain for at least 25 of the 30 days prior to screening. Patients who satisfied entry criteria discontinued their prior NSAID therapy. Following a washout period of 3-15 days (depending on the dose and half-life of the prior therapy), these patients' Walking Pain (Question 1 of the WOMAC Pain Subscale) was assessed on a patient-reported 100 mm visual analogue scale (VAS) ranging from 0 (no pain) to 100 (severe pain). Patients were randomized into the study if they had moderate Walking Pain (at least 40 mm on VAS), a minimum increase (worsening) in Walking Pain (15 mm VAS) and an increase (worsening) in the Investigator's Assessment of Disease Status of 1 point won a 5-point Likert scale ranging from 0 (very well) to 4 (very poor)x, compared with values obtained at screening while patients were receiving their prior NSAID therapy.
Patients were excluded if they had significant renal impairment, clinically significant abnormalities on screening physical or laboratory examinations (calculated creatinine clearance (30 mlumin), Class IIIuIV angina or uncontrolled congestive heart failure, uncontrolled hypertension, stroke or a transient ischaemic attack within 2 yr, active hepatic disease, a history of recent neoplastic disease, acute meniscal injury to the study joint within 2 yr of study entry, arthroscopy in the study joint within 6 months of study entry, weight in excess of 280 pounds (127 kg) or allergy to acetaminophen or NSAIDs. Patients were excluded if they required corticosteroids, warfarin, low-dose aspirin or ticlopidine, or if they had required systemic corticosteroids or intra-articular steroids for joints other than the study joint within the month prior to study entry or to the study joint in the 2 months prior to study entry. Patients with a prior history of gastroduodenal ulcer or GI bleeding were allowed to participate. Patients were also excluded for any other condition which, in the opinion of the investigator, might confound study results, interfere with participation in the study or pose an undue risk to the patient.
Efficacy and safety assessments
Efficacy measurements were obtained at a screening visit, at randomization (after flare and prior to initiation of study therapy) and following 1, 2, 4, 6, 8 and 14 weeks of treatment. At each of these visits, the patients completed the WOMAC and patients and investigators completed global assessments of response to therapy and disease status.
There were three primary end-points for this study: Other end-points included Patient Assessment of Disease Status (100 mm VAS ranging from 0=very well to 100=very poor), Investigator Assessment of Response to Therapy (5-point scale from 0=excellent to 4=none), WOMAC subscales of Stiffness and Physical Function (100 mm VAS ranging from 0=no stiffnessudifficulty to 100=extreme stiffnessudifficulty), Study Joint Tenderness (0-3 scale ranging from 0=no pain to 3=patient states there is pain, winces and withdraws), patient discontinuations due to lack of efficacy, the presence or absence of study joint swelling, and the amount (number of 325 mg tablets) of rescue acetaminophen consumed.
Spontaneously reported adverse experiences were recorded throughout the study. Vital signs were monitored and laboratory investigations, including haematology, chemistry and urinalysis, were performed at all visits. For each clinical adverse experience, the investigator recorded the intensity, relationship to test drug (related or not related), outcome and action taken. The investigator also assessed any laboratory adverse event as drug-related or not drug-related. All adverse experiences were identified and evaluated while the patient and investigator remained blinded to study treatment. Any experience meeting a regulatory definition of 'serious' was also identified by the investigator while still blinded to study treatment. All potential episodes of upper GI perforation, ulceration or bleeding or thrombotic cardiovascular events were submitted to blinded, external review committees for adjudication using prespecified case definitions w8x.
Statistical analysis
The placebo-controlled period (Part 1) tested the hypothesis that etoricoxib 5, 10, 30, 60 and 90 mg once daily would have dose-related clinical efficacy compared with placebo. The primary efficacy evaluation for Part 1 of the study was based on the average treatment response over weeks 2-6 of the treatment period with a modified intention-to-treat approach. Patients with a baseline value and at least one value while on treatment were included in the analysis. In order to show efficacy, treatments had to show a significant difference from placebo for each of the primary end-points. Secondary and other end-points were used for confirmatory purposes only; thus, no adjustment for multiplicity was needed.
Changes from baseline in the primary and secondary end-points were analysed using an analysis of covariance (ANCOVA) model with treatment as the main factor and baseline as a covariate. Disease status at the flareurandomization visit was used as the baseline covariate for Global Assessment of Response to Therapy. Acetaminophen use for rescue purpose was analysed using an analysis of variance (ANOVA) model with treatment as the main factor.
For means and mean changes, comparisons of the MK-0663 doses with placebo were made using the Tukey-Ciminera-Heyse trend test w12x. Between-dose comparisons were made using a pairwise t-test. Ninetyfive per cent confidence intervals were calculated based on a pairwise t-test using the error variance from the ANCOVA or ANOVA model. The confidence limits were used to assess the clinical importance of the observed difference in treatment response w13x.
To examine the treatment response over time, the least squares (LS) mean change from baseline at each study week was plotted against the standard error for each treatment group across the treatment period. The last-value-carried-forward method was used to impute missing values.
There was 096% power to detect treatment differences between the active dose (n=100) and placebo (n=50) groups for the three end-points simultaneously. In active-dose, pairwise comparisons, there was 86% power to detect a difference of 0.5 for Likert scales and 10 mm for VAS with a sample size of 100 patients in each dose group. For reference, clinical doses of rofecoxib resulted in a change of ;15 mm on a VAS scale and 0.5 on a Likert scale w14-16x.
The efficacy evaluation in Part 2 focused on the dose escalation, the consistency of treatment effect over the 14 weeks and comparison of the treatment effect between diclofenac and etoricoxib. The effect of doseescalation from Part 1 to Part 2 was assessed by analysing the difference in treatment response between weeks 6 and 8, based primarily on the graphical representation of the LS mean changes for the three primary end-points. Consistency of the treatment effect over 14 weeks was evaluated by examining plots of LS mean changes from baseline for those patients who maintained the same dose during Part 1 and Part 2 of the study. The comparative efficacies of diclofenac and etoricoxib were evaluated by comparing the LS mean changes from baseline among the Part 2 treatments (diclofenac 150 mg and MK-0663 30, 60 and 90 mg) at weeks 8 and 14. For all analyses in Part 2, the LS mean changes were estimated from an ANCOVA model with treatment as the main factor and baseline as the covariate.
For all adverse experiences reported during Part 1, the difference between the placebo group and the etoricoxib doses was evaluated using the CochranArmitage trend test (a step-down procedure starting with the comparison of the 90 mg dose with placebo) for the overall rate of adverse experiences considered by the investigator to be related to the study drug and for the rates of specific adverse experiences potentially associated with NSAID use or COX-2 inhibition (oedema, hypertension, congestive heart failure, pulmonary oedema, cardiac failure) and the rates of discontinuation due to hypertension and oedema. No inferential testing of safety data was performed in Part 2 due to the absence of a placebo group.
All statistical tests were two-tailed with a=0.050. All P-values were rounded to three decimal places and a rounded P(0.050 was considered statistically significant.
Results
Between June 1998 and February 1999, 952 patients were screened and 617 (65%) were enrolled at 56 clinical centres in the USA. Three hundred thirty-five patients were excluded from study entry for at least one reason, including but not limited to the following: not ARA functional class I, II or IIIufailure to meet OA diagnostic criteria; medical history exclusions; and requiring concomitant therapies not permitted in the trial. All treatment groups had similar baseline characteristics and primary efficacy measures at randomization (Table 1) .
In total, 550 of 617 (89.1%) patients completed the 6-week placebo-controlled period (Part 1). Significantly more patients discontinued study therapy due to lack of efficacy in the placebo and 10 mg etoricoxib groups compared with 30, 60 and 90 mg etoricoxib: seven (11.7%), six (5.1%), 11 (9.6%), four (3.9%), two (1.8%) and two (1.8%) respectively. Two (3.3%), two (1.7%), three (2.7%), three (2.9%), three (2.7%) and six (5.4%) patients in the placebo and 5, 10, 30, 60 and 90 mg etoricoxib groups respectively discontinued due to an adverse experience.
There were no clinically important differences in the rate of discontinuation due to clinical adverse experience among treatment groups. Of the 550 patients who completed the 6-week placebo-controlled period and entered into Part 2 (198, 102, 148 and 102 in the 30, 60 and 90 mg etoricoxib and diclofenac groups respectively), 510 (91.1%) completed the eight-week active comparator-controlled period.
Three (1.5%), two (2.0%), six (4.1%) and five (4.9%) patients in the 30, 60 and 90 mg etoricoxib and diclofenac groups respectively discontinued due to an adverse experience. There were no significant differences in the rates of discontinuation due to lack of efficacy or adverse experiences between groups in Part 2.
Only six patients were discontinued due to a protocol deviation. Twenty-one patients (3.4%) were excluded from one or more efficacy analyses due to missing baseline data or absence of on-treatment data; absence of data was determined as prespecified in the protocol and prior to unblinding. All available data from each of these 27 patients were included in all safety analyses.
Efficacy
Placebo-controlled period (Part 1). The response over time for the three primary end-points is presented in Fig. 2 . When averaged over weeks 2-6 of the treatment period, all doses of etoricoxib (5-90 mg) demonstrated greater efficacy compared with placebo, as assessed by all three primary end-points: WOMAC Pain Subscale (VAS), Patient Global Assessment of Response to Therapy (Likert) and Investigator Global Assessment of Disease Status (Likert). The etoricoxib doses and placebo exhibited a strong dose-related trend for improvement in all primary end-points. The maximal degree of improvement with etoricoxib was similar for 60 and 90 mg vs placebo for all primary end-points. However, the treatment responses for 60 mg were numerically greater. In general, the effect size for the 30 mg dose was approximately half to two-thirds of that with MK-663 60 or 90 mg (Fig. 2, Table 2 ).
Improvement from baseline, assessed by the primary end-points, with etoricoxib 60 and 90 mg was significantly greater than with 5 and 10 mg (P(0.023). Etoricoxib 60 mg was significantly different from 30 mg for all primary end-points (P(0.003); 90 mg was different from 30 mg for two of the three end-points (Fig. 2) .
These results were consistent with those for all secondary end-points (Table 2) .
Active comparator-controlled period (Part 2). In general, improvements seen at week 2 (Part 1) were sustained without significant changes across the 14-week treatment period for patients receiving etoricoxib 30, 60 or 90 mg during Parts 1 and 2 (Fig. 3) .
Patients who received placebo or 5 or 10 mg etoricoxib in Part 1 and then switched to diclofenac or etoricoxib 30 mg in Part 2 showed improvements in OA signs and symptoms, as assessed by the three primary end-points, after 2 weeks of Part 2 therapy. On average, the additional benefit was between 28. Placebo-controlled period (Part 1). The percentages of patients with adverse experiences considered drugrelated by investigators were generally similar across all treatment groups; those occurring in more than 3% of patients are presented in Table 3 .
Eighteen (2.9%) of 617 patients discontinued due to a clinical adverse experience which began during Part 1 (Table 3) . Four patients discontinued for digestive adverse experiences, four for nervous system adverse experiences (including dizziness), five for musculoskeletal adverse experiences and one each for various unrelated experiences, including urinary tract infection, anxiety disorder, rash, atrial fibrillation, oedema and oliguria, and astrocytoma. These events were not clustered in any one particular treatment group. Statistical analyses revealed no significant differences between groups.
Individual NSAID-type GI adverse experiences of abdominal pain, acid reflux, dyspepsia, epigastric discomfort, nausea or vomiting considered to be related to the study drug occurred in 0-5 patients in each treatment group. Those reported in 3% or more of patients are included in Table 3 . Of note, there was a small numerical increase in the percentage of patients experiencing diarrhoea in the etoricoxib 10, 30, 60 and Discontinuation due to lack of efficacy
Study joint tenderness (0-3) Confidence intervals that include zero generally indicate that the etoricoxib dose was not significantly different from placebo. placebo. No significant differences among groups were noted, nor were there significant dose-related trends in the incidence of these adverse experiences.
Renovascular adverse experiences were examined specifically. Drug-related hypertension and oedema occurred in fewer than 3% of patients in each group. Among those experiences considered to be related to study drug by investigators, hypertension was reported by one patient each in the placebo (1.7%) and 30 mg etoricoxib (1.0%) groups, and increased blood pressure in one patient each in the placebo (1.7%) and 10 mg etoricoxib groups (0.9%). Reports of drug-related oedema or lower extremity oedema occurred in one patient each in the placebo (1.7%) and 5 mg etoricoxib (0.9%) groups, two patients in the 10 mg group (1.8%), three (2.7%) patients in the 60 mg and three (2.7%) patients in the 90 mg group. No statistically significant or clinically relevant dose-related trends were noted for oedema or hypertension adverse experiences.
Ten patients had one or more serious adverse experiences; none were considered by investigators to be related to study drug. Four patients, in the 30, 60 or 90 mg etoricoxib groups, had serious cardiovascular adverse experiences (deep venous thrombosis, chest pain associated with angina pectoris and atrial fibrillation, atrial fibrillation and ventricular tachycardia); none were confirmed as cardiovascular thrombotic events by a blinded external review committee. The remaining serious adverse experiences were isolated events (dyspnoea, astrocytoma, renal colic, joint prosthesis complication) reported in one or two patients (basal cell carcinoma; 5 and 10 mg groups). No episodes of upper GI perforation, ulceration or bleeding were reported in Part 1, although one patient receiving 90 mg etoricoxib had a serious lower GI bleed. No episodes of congestive heart failure or acute renal failure were reported.
Eight patients (1.3%) had drug-related laboratory adverse experiences, including alanine aminotransferase (ALT) increase, aspartate aminotransferase (AST) increase, increased serum creatinine, increased alkaline phosphatase, decreased haemoglobin, decreased leucocytes or hyperkalaemia. One (0.2%) patient receiving 10 mg etoricoxib discontinued due to a laboratory adverse experiences of increased ALTuAST. No doserelated trends or clinically important patterns were observed in specific laboratory adverse experiences.
Active comparator-controlled period (Part 2). The overall percentage of patients with drug-related adverse experiences was generally similar across treatment groups for Parts 1 and 2 (Table 3) . Only laboratory adverse experiences occurred at a rate of 3% or more in any individual treatment group during Part 2.
No new dose-related trends or clinically important patterns were observed in specific clinical adverse experiences during Part 2. With any serious AE In Part 2, 14 patients discontinued due to a clinical adverse experience. Of these, six were in the digestive system, two were episodes of dizziness (one associated with irregular heartbeat), two were skin adverse experiences and four were other adverse experiences (Menière's disease, taste loss, pneumonia and leg pain). All clinical adverse experiences resulting in discontinuation from the diclofenac group were GI-related; no other trends were seen in adverse experiences resulting in discontinuation.
Individual specific NSAID-type GI experiences (abdominal pain, dyspepsia, heartburn, nausea, diarrhoea or vomiting) considered to be related to the study drug were reported in fewer than 3% of patients in each treatment group. No one group had a specific increase compared with other groups and no new trends were noted for these events.
An examination of renovascular adverse experiences showed that 1% or fewer of patients in each group had an adverse experience of lower extremity oedema. One patient in each of the etoricoxib groups and three patients in the diclofenac group had an adverse experience of hypertension.
Serious adverse experiences were reported in three patients in each group except the 60 mg etoricoxib group; none were considered related to study drug. With the exception of malignancies (n=2; 30 mg) and cellulitis (n=2; 90 mg and diclofenac), all were isolated occurrences (arthralgia, abdominal hernia, cholecystitis, obstructive bronchitis). One patient in the diclofenac group had a serious lower GI bleed. No cardiovascular thrombotic event or episode of upper GI perforation, ulceration or bleeding was reported in Part 2.
Overall, nine patients (1.6%) had drug-related laboratory adverse experiences during Part 2: two patients on 90 mg etoricoxib and seven on diclofenac. The most common laboratory adverse experiences among the diclofenac-treated patients were increased ALTuAST (Table 4) . Two (0.4%) patients receiving diclofenac discontinued due to laboratory adverse experiences, one for increased ALTuAST and one for increased serum creatinine and decreased haemoglobin.
Discussion
In this two-part, 14-week, dose-ranging study, etoricoxib once daily caused clinically significant improvements in the signs and symptoms of OA of the knee. Compared with placebo, there were statistically significant improvements in the three primary end-points for all etoricoxib doses, the effect sizes exhibiting a strong dose-related trend for the 5-60 mg doses. The 90 mg dose did not exhibit additional therapeutic benefits compared with 60 mg. Improvements seen in the first 6 week treatment period (Part 1) for etoricoxib 30, 60 and 90 mg were sustained for an additional 8 weeks (Part 2). The degree of improvement with etoricoxib 60 and 90 mg (vs placebo) exceeded this trial's predefined criteria for clinically important effects for all primary end-points. As the effectiveness of etoricoxib appeared to be maximal at 60 mg, this dose was carried forward as the recommended dose in Phase III trials. Further study will be required to define the efficacy profile of etoricoxib 60 mg in patients with OA.
Etoricoxib was generally well tolerated in this study. Most adverse experiences were transient and selflimited; few resulted in discontinuation of study therapy. No statistically significant, dose-related trends were identified in the rates of hypertension or oedema adverse experiences, and none of these experiences occurred at a rate of more than 3% in any treatment group. However, the sample size in this trial is too small to make definitive conclusions about the safety and tolerability profile of etoricoxib. This study was primarily designed as a dose-ranging study and therefore added study will be required to further define etoricoxib's safety profile. This holds true for generalizations to older patient populations with comorbid conditions, such as congestive heart failure and uncontrolled hypertension, who were excluded from this study.
Current American College of Rheumatology guidelines for the treatment of OA specifically mention the role of COX-2 inhibitors in combination with exercise, education and social support w17x. However, the variable response to NSAIDs in individual patients is well documented, and no specific factors have been shown to predict treatment failure with individual NSAIDs among patients with OA w18x. Physicians often manage treatment failure with NSAIDs by switching patients from one NSAID to another until they identify a compound which provides relief w19x. Currently, only two COX-2 selective NSAIDs are available, which limits choices for patients and physicians interested in using COX-2 inhibitors.
It should be noted that previous studies with NSAIDs have demonstrated a plateau of clinical analgesic efficacy, although additional anti-inflammatory effects might be seen with higher doses, which provides a rationale for the use of higher doses in chronic conditions with inflammatory components, such as rheumatoid arthritis w20x. This study defined a maximally effective clinical dose of etoricoxib in patients with OA, 60 mg. Identification of a clinically maximal dose is important information for clinicians, and may help prevent the use of higher doses than necessary to provide relief of painful symptoms without exposing patients to higher risks of adverse experiences.
In this study, etoricoxib doses of 5, 10, 30, 60 and 90 mg were generally well tolerated and the 30, 60 and 90 mg doses were generally effective in OA patients. All doses studied were generally safe and well tolerated for the 14 week treatment period. However, with regard to discontinuations due to clinical adverse experiences, there was a numerical increase in the 90 mg group compared with the other doses studied, in Parts 1 and 2. While no significant differences were noted between groups and the number of discontinuations on 90 mg etoricoxib and diclofenac was similar in Part 2, taking into account both safety and efficacy, the 60 mg dose provided the optimal benefiturisk relationship. With a greater degree of in vitro selectivity, a favourable pharmacokinetic profile and proven efficacy in the OA in this study, etoricoxib may prove to be an important addition to the therapeutic armamentarium. Further clinical studies with etoricoxib will explore more fully the therapeutic potential and tolerability of this selective COX-2 inhibitor in a broad spectrum of inflammatory conditions, cancer and neurological diseases.
